Ann: 2023 Annual Report to shareholders, page-168

First 168 Last

Share
Profile

Follow
Flash99

727 Posts.

167

28/04/24

16:30

Post #: 73544838
Share

Originally posted by hottod: ↑

Yes, Opthea’s pivotal trials are very large, but they were never going to be in ~100 patients, such as can be found in some rare disease trials.

Opthea's Phase 3 trails are testing sozinibercept in combination with the two leading wet AMD therapies, Lucentis and Eylea.

A comparison with patient numbers in the Phase 3 trials used for the approval of these two drugs shows that Lucentis was assessed in three trials with a total of 1,323 patients and Eylea in two trials with a total of 2,412 patients.

Additionally. Opthea’s pivotal trials are more complex that those conducted for Lucentis and Eylea in wet AMD. Opthea is not only testing its drug in combination with two different drugs in two different trials, it’s also assessing two different dosing regimens; thus 3 arms are required in each trial.

Each trial has 990 patients, with 330 in each arm. The trials are designed for ~90% power and 5% type 1 error rate.

Can’t help beyond that as my knowledge and understanding of clinical trial design and statistics is very basic – perhaps someone with more knowledge might be able to help on the OPT forum?

Expand

Thanks hottod. Knowledgeable as always. Happy to leave the trial design over there in the past as I'm sure it was discussed at length back then.

NEU Price at posting: $18.65 Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

RCE

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

First 168 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.85		Change -0.110(0.85%)		Mkt cap ! $1.598B

Open	High	Low	Value	Volume
$12.82	$13.05	$12.53	$6.559M	511.8K

Buyers (Bids)

No.	Vol.	Price($)
1	1657	$12.83

Sellers (Offers)

Price($)	Vol.	No.
$12.85	6303	1

View Market Depth

No.	Vol.	Price($)
1	1657	12.830
2	3312	12.750
1	1224	12.730
3	3229	12.720
1	1299	12.700

Price($)	Vol.	No.
12.850	6303	1
12.890	7731	5
12.910	1229	1
12.920	1474	2
12.950	1299	1

Last trade - 16.10pm 17/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: 2023 Annual Report to shareholders, page-168

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 2023 Annual Report to shareholders, page-168

Top Stories

ASX Market Close: Bourse spins in circles as Israel-Iran conflict weighs | June 17, 2025

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Recce locks in $30M to boost commercialisation across ASEAN region

VBX Ltd jumps 15% on ASX debut as newest Oz bauxite player

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News